Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward

Executive Summary

Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.


Related Content

AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process
Merck Victrelis Glowing Recommendation From NICE At Odds With IQWiG
Germany’s Pricing Revolution: Why The World Should Be Watching
AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
J&J’s Incivo Shows “Hints” Of Added Benefit, Says Germany’s IQWiG
Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health
AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's Brilinta Approved With Aspirin Warning
Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts